Bright Minds Biosciences Inc.
DRUG
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 30.44% | -25.39% | -17.24% | -35.17% | -50.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.44% | -51.51% | -116.89% | -76.02% | -28.24% |
| Operating Income | 5.44% | 51.51% | 116.89% | 76.02% | 28.24% |
| Income Before Tax | 102.86% | 51.77% | 114.47% | 71.91% | 28.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 102.86% | 51.77% | 114.47% | 71.91% | 28.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 102.86% | 51.77% | 114.47% | 71.91% | 28.05% |
| EBIT | 5.44% | 51.51% | 116.89% | 76.02% | 28.24% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 101.77% | 59.34% | 112.23% | 76.17% | 32.83% |
| Normalized Basic EPS | 101.79% | 59.35% | 112.23% | 76.18% | 32.82% |
| EPS Diluted | 101.76% | 58.81% | 112.13% | 75.92% | 32.58% |
| Normalized Diluted EPS | 101.64% | 59.35% | 111.73% | 76.18% | 32.82% |
| Average Basic Shares Outstanding | 60.45% | 18.62% | 18.34% | 17.86% | 7.13% |
| Average Diluted Shares Outstanding | 72.84% | 18.62% | 23.25% | 17.86% | 7.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
